Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
94,179,674
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
16,164,902
-
Shares change
-
+16,164,902
-
Total reported value, excl. options
-
$463,124,000
-
Value change
-
+$463,124,002
-
Number of buys
-
49
-
Price
-
$28.65
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) as of Q3 2018
49 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock as of Q3 2018.
Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16,164,902 shares
of 94,179,674 outstanding shares and own 17% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (3,792,169 shares), FMR LLC (2,717,838 shares), PERCEPTIVE ADVISORS LLC (2,587,953 shares), ORBIMED ADVISORS LLC (1,914,282 shares), RA CAPITAL MANAGEMENT, LLC (1,701,017 shares), JANUS HENDERSON GROUP PLC (524,744 shares), PRICE T ROWE ASSOCIATES INC /MD/ (433,905 shares), BlackRock Inc. (419,286 shares), Vanguard Group Inc (247,923 shares), and Artal Group S.A. (200,000 shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.